PHATHOM PHARMACEUTICALS, INC. Marketing and Advertising Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Marketing and Advertising Expense of $61.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-02-26
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for the quarter ending 2024-12-31 was $20.30M.
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for the quarter ending 2024-09-30 was $17.50M.
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for the quarter ending 2024-06-30 was $16.70M.
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for the quarter ending 2024-03-31 was $6.80M.
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for fiscal 2025 was $61.30M, a 0.00% change from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. marketing and advertising expense for fiscal 2024 was $61.30M.
| Period end | Marketing and Advertising Expense 3 month | Marketing and Advertising Expense 6 month | Marketing and Advertising Expense 9 month | Marketing and Advertising Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $61.30M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $20.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.80M derived: sum of 2 quarters · filed 2026-02-26 | $54.50M derived: sum of 3 quarters · filed 2026-02-26 | $61.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $17.50M 10-Q · filed 2024-11-07 | $34.20M derived: sum of 2 quarters · filed 2024-11-07 | $41.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $16.70M 10-Q · filed 2024-08-08 | $23.50M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $6.80M 10-Q/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |